Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 3
1974 1
1975 1
1977 1
1986 1
1989 1
1990 1
1991 2
1992 8
1993 14
1994 13
1995 12
1996 12
1997 12
1998 14
1999 16
2000 9
2001 22
2002 30
2003 38
2004 43
2005 48
2006 42
2007 41
2008 36
2009 49
2010 35
2011 51
2012 41
2013 62
2014 47
2015 59
2016 68
2017 61
2018 56
2019 80
2020 78
2021 68
2022 51
2023 44
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

1,157 results

Results by year

Filters applied: . Clear all
The following terms were not found in PubMed: RP11-761B3.1, RP11-761B3.1
Page 1
Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol JB, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C. Duployez N, et al. Blood. 2016 May 19;127(20):2451-9. doi: 10.1182/blood-2015-12-688705. Epub 2016 Mar 15. Blood. 2016. PMID: 26980726 Free PMC article.
Mutations in genes activating tyrosine kinase signaling (including KIT, N/KRAS, and FLT3) were frequent in both subtypes of CBF-AML. In contrast, mutations in genes that regulate chromatin conformation or encode members of the cohesin complex were observed with high freque …
Mutations in genes activating tyrosine kinase signaling (including KIT, N/KRAS, and FLT3) were frequent in both subtypes of CBF-AML. …
Sarcoma care in the era of precision medicine.
Wallander K, Öfverholm I, Boye K, Tsagkozis P, Papakonstantinou A, Lin Y, Haglund de Flon F. Wallander K, et al. J Intern Med. 2023 Dec;294(6):690-707. doi: 10.1111/joim.13717. Epub 2023 Sep 7. J Intern Med. 2023. PMID: 37643281 Review.
In this review, we present diagnostic, therapeutic, and prognostic molecular markers that are, or might soon be, used clinically. For sarcoma diagnostics, there are specific fusions highly supportive or pathognomonic for a diagnostic entity-for instance, SYT::SSX in synovi …
In this review, we present diagnostic, therapeutic, and prognostic molecular markers that are, or might soon be, used clinically. For sarcom …
Beyond BRAF in melanoma.
Daud A, Bastian BC. Daud A, et al. Curr Top Microbiol Immunol. 2012;355:99-117. doi: 10.1007/82_2011_163. Curr Top Microbiol Immunol. 2012. PMID: 21826607 Review.
Alterations in the RAS-RAF-MAP kinase and PI3-kinase signaling pathways are commonly altered in melanoma. Mutations in BRAF, NRAS, KIT, and GNAQ occur in a mutually exclusive pattern and lead to MAP-kinase activation. ...This concept follows the paradigm established by the …
Alterations in the RAS-RAF-MAP kinase and PI3-kinase signaling pathways are commonly altered in melanoma. Mutations in BRAF, NRAS, KIT
Applicability of human-specific STR systems, GlobalFiler PCR Amplification Kit, Investigator 24plex QS Kit, and PowerPlex Fusion 6C in chimpanzee (Pan troglodytes).
Singh A, Sahajpal V, Thakur M, Sharma LK, Chandra K, Bhandari D, Sharma A. Singh A, et al. BMC Res Notes. 2021 May 29;14(1):212. doi: 10.1186/s13104-021-05632-6. BMC Res Notes. 2021. PMID: 34051836 Free PMC article.
This study aimed to validate the cross-reactivity of three widely known human-specific STR identification systems i.e. GlobalFiler PCR Amplification Kit, Investigator 24plex QS Kit, and PowerPlex Fusion 6C in chimpanzee. RESULTS: The present study reve …
This study aimed to validate the cross-reactivity of three widely known human-specific STR identification systems i.e. GlobalFiler PC …
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
Gotlib J. Gotlib J. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):34-46. doi: 10.1182/hematology.2022000368. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485158 Free PMC article. Review.
With avapritinib, the achievement of molecular remission of KIT D816V and improved survival compared with historical therapy suggests a potential to affect disease natural history. BLU-263 and bezuclastinib are KIT D816V inhibitors currently being tested in trials o …
With avapritinib, the achievement of molecular remission of KIT D816V and improved survival compared with historical therapy suggests …
NTRK fusions and Trk proteins: what are they and how to test for them.
Weiss LM, Funari VA. Weiss LM, et al. Hum Pathol. 2021 Jun;112:59-69. doi: 10.1016/j.humpath.2021.03.007. Epub 2021 Mar 29. Hum Pathol. 2021. PMID: 33794242 Review.
The NTRK genes include a family of three genes, NTRK1, NTRK2, and NTRK3, which are associated with fusions with a variety of partner genes, leading to upregulation of three proteins, TrkA, TrkB, and TrkC. ...With new FDA-approved treatments available and effective in treat …
The NTRK genes include a family of three genes, NTRK1, NTRK2, and NTRK3, which are associated with fusions with a variety of partner …
New therapeutic agents in gastrointestinal stromal tumours.
Falkenhorst J, Hamacher R, Bauer S. Falkenhorst J, et al. Curr Opin Oncol. 2019 Jul;31(4):322-328. doi: 10.1097/CCO.0000000000000549. Curr Opin Oncol. 2019. PMID: 31033566 Review.
PURPOSE OF REVIEW: The aim of this study was to provide an update on the most recent developments regarding systemic treatments in the various molecular subtypes of gastrointestinal stromal tumour (GIST). RECENT FINDINGS: Several novel direct inhibitors of KIT and PDGFRA h …
PURPOSE OF REVIEW: The aim of this study was to provide an update on the most recent developments regarding systemic treatments in the vario …
The role of gene fusions in melanocytic neoplasms.
Quan VL, Panah E, Zhang B, Shi K, Mohan LS, Gerami P. Quan VL, et al. J Cutan Pathol. 2019 Nov;46(11):878-887. doi: 10.1111/cup.13521. Epub 2019 Jun 20. J Cutan Pathol. 2019. PMID: 31152596 Review.
Spitz tumors with ALK, NTRK1, and NTRK3 fusions have characteristic morphologic features. BRAF and MAP3K8 fusions, in particular, tend to be epithelioid, high grade, and more frequent in Spitz melanoma than other fusion subtypes. Sporadic cases of pigmented e …
Spitz tumors with ALK, NTRK1, and NTRK3 fusions have characteristic morphologic features. BRAF and MAP3K8 fusions, in particul …
Future directions in soft tissue sarcoma treatment.
Hall F, Villalobos V, Wilky B. Hall F, et al. Curr Probl Cancer. 2019 Aug;43(4):300-307. doi: 10.1016/j.currproblcancer.2019.06.004. Epub 2019 Jun 20. Curr Probl Cancer. 2019. PMID: 31229264 Review.
In this review, we discuss the current state of STS diagnostics and treatment and explore some of the more promising areas in which progress is being made. We discuss therapies targeting PDGFRalpha/KIT, beta-Catenin/APC/NOTCH, IDH-1/2 mutations, MDM2 amplifications, EZH2/I …
In this review, we discuss the current state of STS diagnostics and treatment and explore some of the more promising areas in which progress …
Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with RUNX1-RUNX1T1 or CBFB-MYH11 Fusions.
Qin W, Chen X, Shen HJ, Wang Z, Cai X, Jiang N, Hua H. Qin W, et al. Turk J Haematol. 2022 Jun 1;39(2):84-93. doi: 10.4274/tjh.galenos.2022.2021.0641. Epub 2022 Apr 21. Turk J Haematol. 2022. PMID: 35445594 Free PMC article. Review.
RESULTS: In the whole cohort, the most commonly mutated genes were c-KIT (33.6%) and NRAS (33.6%), followed by FLT3 (18.7%), KRAS (13.4%), RELN (8.2%), and NOTCH1 (8.2%). ...Significantly higher white blood cell counts were found in inv(16)/t(16;16) AML patients with c- …
RESULTS: In the whole cohort, the most commonly mutated genes were c-KIT (33.6%) and NRAS (33.6%), followed by FLT3 (18.7%), KRAS (13 …
1,157 results